NO996274L - CD154-blokkering for terapeutisk protein-inhibitorsyndrom - Google Patents

CD154-blokkering for terapeutisk protein-inhibitorsyndrom

Info

Publication number
NO996274L
NO996274L NO996274A NO996274A NO996274L NO 996274 L NO996274 L NO 996274L NO 996274 A NO996274 A NO 996274A NO 996274 A NO996274 A NO 996274A NO 996274 L NO996274 L NO 996274L
Authority
NO
Norway
Prior art keywords
blockage
protein inhibitor
therapeutic protein
exogenous protein
inhibitor syndrome
Prior art date
Application number
NO996274A
Other languages
English (en)
Norwegian (no)
Other versions
NO996274D0 (no
Inventor
Burt Adelman
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO996274D0 publication Critical patent/NO996274D0/no
Publication of NO996274L publication Critical patent/NO996274L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
NO996274A 1997-06-20 1999-12-17 CD154-blokkering for terapeutisk protein-inhibitorsyndrom NO996274L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20
PCT/US1998/012773 WO1998058672A1 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for therapeutic protein inhibitor syndrome

Publications (2)

Publication Number Publication Date
NO996274D0 NO996274D0 (no) 1999-12-17
NO996274L true NO996274L (no) 2000-02-18

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996274A NO996274L (no) 1997-06-20 1999-12-17 CD154-blokkering for terapeutisk protein-inhibitorsyndrom

Country Status (25)

Country Link
US (1) US20020119151A1 (bg)
EP (1) EP1034001B1 (bg)
JP (1) JP2002504910A (bg)
KR (1) KR100567998B1 (bg)
CN (2) CN1651071A (bg)
AT (1) ATE272408T1 (bg)
AU (1) AU733062B2 (bg)
BG (1) BG64436B1 (bg)
BR (1) BR9810755A (bg)
CA (1) CA2294138A1 (bg)
CZ (1) CZ295805B6 (bg)
DE (1) DE69825473T2 (bg)
EA (1) EA002512B1 (bg)
EE (1) EE9900587A (bg)
ES (1) ES2226152T3 (bg)
HK (1) HK1031825A1 (bg)
HU (1) HUP0002048A3 (bg)
IL (1) IL133305A0 (bg)
IS (1) IS2097B (bg)
NO (1) NO996274L (bg)
NZ (1) NZ502051A (bg)
PT (1) PT1034001E (bg)
SK (1) SK285962B6 (bg)
TR (1) TR199903141T2 (bg)
WO (1) WO1998058672A1 (bg)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20011021A3 (cs) * 1998-09-21 2001-10-17 Genetics Institute, Inc. Způsoby tlumení imunitní odpovědi na terapeutické proteiny
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US6797263B2 (en) 2000-05-12 2004-09-28 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
IES20030299A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
CN1835976B (zh) * 2003-06-13 2012-06-13 比奥根艾迪克Ma公司 无糖基抗-cd154(cd40配体)抗体及其用途
AU2004253868B2 (en) * 2003-06-13 2011-06-16 Biogen Ma Inc. Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
PT1682178E (pt) 2003-11-04 2010-10-21 Novartis Vaccines & Diagnostic Métodos de terapêutica para cancros que expressam o antigénio cd40
RS20070027A (en) 2004-07-26 2008-11-28 Biogen Idec Ma Inc., Anti-cd154 antibodies
US20070286855A1 (en) * 2004-08-03 2007-12-13 Mayo Foundation For Medical Education And Research Improving treatments
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
WO2007124299A2 (en) 2006-04-21 2007-11-01 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012158789A2 (en) 2011-05-17 2012-11-22 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
ATE356634T1 (de) * 1997-01-10 2007-04-15 Biogen Idec Inc Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln

Also Published As

Publication number Publication date
JP2002504910A (ja) 2002-02-12
BG104092A (bg) 2000-10-31
EE9900587A (et) 2000-08-15
HUP0002048A3 (en) 2002-09-30
SK285962B6 (sk) 2007-12-06
IS2097B (is) 2006-04-12
ES2226152T3 (es) 2005-03-16
HK1031825A1 (en) 2001-06-29
AU8153698A (en) 1999-01-04
WO1998058672A1 (en) 1998-12-30
US20020119151A1 (en) 2002-08-29
DE69825473D1 (de) 2004-09-09
NZ502051A (en) 2001-04-27
DE69825473T2 (de) 2005-08-04
CN1651071A (zh) 2005-08-10
HUP0002048A2 (hu) 2000-10-28
CN1261285A (zh) 2000-07-26
EA002512B1 (ru) 2002-06-27
BG64436B1 (en) 2005-02-28
IL133305A0 (en) 2001-04-30
KR100567998B1 (ko) 2006-04-07
EP1034001A1 (en) 2000-09-13
AU733062B2 (en) 2001-05-03
CA2294138A1 (en) 1998-12-30
PT1034001E (pt) 2004-12-31
KR20010013964A (ko) 2001-02-26
IS5274A (is) 1999-11-26
CZ295805B6 (cs) 2005-11-16
TR199903141T2 (xx) 2000-09-21
BR9810755A (pt) 2000-08-15
EA200000059A1 (ru) 2000-08-28
EP1034001B1 (en) 2004-08-04
CZ458899A3 (cs) 2000-04-12
ATE272408T1 (de) 2004-08-15
SK180399A3 (en) 2000-06-12
NO996274D0 (no) 1999-12-17

Similar Documents

Publication Publication Date Title
NO996274D0 (no) CD154-blokkering for terapeutisk protein-inhibitorsyndrom
WO2001024816A3 (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
SE9800836D0 (sv) New Compounds
UA66767C2 (uk) Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
DK0682664T3 (da) Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler
AU2002360592A1 (en) Inhibitors of hepatitis c virus
BR9811099A (pt) Inibidores de urocinase
ATE170868T1 (de) Peptid-phosphinyloxymethyl-ketonen als inhibitoren von interleukin-1 beta- konvertierenden enzymen
DK641589A (da) N-aryl-azetidinoner, fremgangsmaade til deres fremstilling og deres anvendelse som elastaseinhibitorer
EA200100732A1 (ru) Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
WO2000041508A3 (en) Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
DK0584247T3 (da) Sammensætninger til behandling af kronisk træthedssyndrom
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
EP1185283A4 (en) NEW THERAPEUTIC USE OF A VIRAL INJECTION MODULATING PROTEIN TO PREVENT EXHAUST FROM FOREIGN TRANSPLANTS
FI962264A0 (fi) Tulehduksia aiheuttavan sytokiinin muodostumisen inhibiittori, joka käsittää polyprenyylin johdannaisia aktiivisena ainesosana
WO2003099212A3 (en) Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
AU9294698A (en) Methods and compositions for enhanced wound healing
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
UA94022C2 (ru) Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
DK0537915T3 (da) N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
NO20001846D0 (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
WO2004017902A3 (en) Ubiquitin and ubiquitin related molecules for treatment and prevention of harmful activation of the immune system
BR9612245A (pt) Inibidor de óxido nitrico (no) sintase para tratamento ou prevenção de diabetes tipo ii
WO2003064378A3 (de) Verbindungen, die faktor xa-aktivität

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application